健脾消积口服液结合西药治疗Ⅱ、Ⅲ期肝癌40例的临床观察

作者	单位
黄智芬	广西医科大学附属肿瘤医院中西医结合科
黎汉忠	广西医科大学附属肿瘤医院中西医结合科
施智严	广西灵山县中医院肿瘤科
谭志强	广西医科大学附属肿瘤医院中西医结合科
张作军	广西医科大学附属肿瘤医院中西医结合科
陈闯	广西医科大学附属肿瘤医院中西医结合科
陆永奎	广西医科大学附属肿瘤医院中西医结合科

摘要点击次数: 1289

全文下载次数: 1371

中文摘要:

目的:探讨健脾消积口服液结合西药治疗Ⅱ、Ⅲ期肝癌的临床疗效。方法:将75例Ⅱ、Ⅲ期肝癌患者按数字表法随机分为治疗组（40例）与对照组（35例）,两组患者均采用相同的西药疗法,治疗组同时加用健脾消积口服液治疗。观察近期疗效、生存质量、中医证候变化、免疫学等指标变化。结果:治疗组与对照组完全缓解率分别为5％、0,稳定分别为62.5％、37.1％;生存质量:总改善率分别为47.5％、25.7％;证候改善率分别为80.0％、54.3％,两组间比较,差异均有显著性（P<0.01）。两组治疗前T淋巴细胞亚群比较差异无显著性,治疗组治疗后与治疗前比较,除CD₈外,CD₃、C₃D和CD₄。/CD₈比值改善,差异均有显著性（P<0.05或P<0.01）,且优于对照组治疗后（P<0.05或P<0.01）。结论:健脾消积口服液可提高Ⅱ、Ⅲ期肝癌患者的生存质量,延长生存时间,并有提高细胞免疫功能的作用。

英文摘要:

Objective: To study the clinical effect of Jianpi Xiaoji Oral Liquid (JXOL) in treating patients with late stage hepatocarcinoma for supplementary treatment. Methods: Seventy-five patients were randomly divided into the treated group (40 patients) and the control group (35 patients). Both groups received the same western medical treatment, including the supporting therapy and analgesia, to the treated group JXOL was added. The short-term effect, quality of life, changes of TCM Syndrome and immunologic criteria were observed. Results; The complete remission (CR) rate in the treated group and the control group was 5% and 0 respectively, stable rate was 62.5% and 37.1% respectively, quality of life: improving rate was 47.5% and 25.7%, TCM Syndrome improving rate was 80 % and 54.3 % respectively, there was significant difference in comparison of the two groups (P<0.01) . T-lymphocyte subset were not different significantly in the two groups before treatment (P>0.05). After treatment, the criteria (CD3, CD4, CD4/CD8 ratio), except CD8, improued significantly in the treated group (P<0.05 or P<0.01) and were better than those in the control group (P<0.05 or P< 0.01). Conclusion: JXOL could raise guality of life of hepatocarcinoma patients in the late stage, prolong their survival time and elevate their cellular immunity.

关闭